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14 Abstract
15 Intermittent energy restriction (IER) involves short periods of severe energy restriction interspersed with periods of adequate energy intake,
16 and can induce weight loss. Insulin sensitivity is impaired by short-term, complete energy restriction, but the effects of IER are not well known.
17 In randomised order, fourteen lean men (age: 25 (SD 4) years; BMI: 24 (SD 2) kg/m2; body fat: 17 (4)%) consumed 24-h diets providing 100%
18 (10 441 (SD 812) kJ; energy balance (EB)) or 25% (2622 (SD 204) kJ; energy restriction (ER)) of estimated energy requirements, followed by an
19 oral glucose tolerance test (OGTT; 75 g of glucose drink) after fasting overnight. Plasma/serum glucose, insulin, NEFA, glucagon-like peptide-1
20 (GLP-1), glucose-dependent insulinotropic peptide (GIP) and ﬁbroblast growth factor 21 (FGF21) were assessed before and after (0 h) each
21 24-h dietary intervention, and throughout the 2-h OGTT. Homoeostatic model assessment of insulin resistance (HOMA2-IR) assessed the
22 fasted response and incremental AUC (iAUC) or total AUC (tAUC) were calculated during the OGTT. At 0 h, HOMA2-IR was 23% lower after
23 ER compared with EB (P< 0·05). During the OGTT, serum glucose iAUC (P< 0·001), serum insulin iAUC (P< 0·05) and plasma NEFA tAUC
24 (P< 0·01) were greater during ER, but GLP-1 (P= 0·161), GIP (P= 0·473) and FGF21 (P= 0·497) tAUC were similar between trials. These
25 results demonstrate that severe energy restriction acutely impairs postprandial glycaemic control in lean men, despite reducing HOMA2-IR.
26 Chronic intervention studies are required to elucidate the long-term effects of IER on indices of insulin sensitivity, particularly in the absence of
27 weight loss.
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29 Obesity is the result of chronic mismanagement of energy balance
30 (EB) and is associated with several chronic diseases(1). Recent
31 analyses project the prevalence of obesity to continue to
32 increase(2), with part of this increase attributable to a greater
33 number of lean individuals gaining weight throughout adult-
34 hood(3). Daily energy restriction (ER) of 20–50% of estimated
35 energy requirements (EER) is frequently used as a method of
36 managing EB(4), yet data suggest that only approximately 40% of
37 individuals manage to achieve long-term weight loss(5). This may
38 be owing to the requirement for daily adherence to the diet in
39 order to achieve a sufﬁciently large energy deﬁcit for weight loss(6).
40Intermittent energy restriction (IER), often termed ‘inter-
41mittent fasting’, has become the subject of considerable
42research attention as an alternative to continuous ER(7). Typi-
43cally, IER permits consumption of an ad libitum or adequate
44energy diet (i.e. approximately 100% EER) punctuated by short
45periods (24–48 h) of severe (approximately 25% EER) or com-
46plete ER. Previous studies have demonstrated 2–16 kg of weight
47loss after 3–20 weeks of IER, which is comparable to losses
48induced with daily ER(8). With IER, this weight loss may be
49facilitated by a subjective and hormonal appetite response
50conducive to the maintenance of a negative EB(9–11). As such,
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51 IER may be an effective alternative weight management strategy
52 to traditional continuous moderate ER.
53 By nature, IER requires individuals to undergo repeated
54 cycles of acute severe ER and refeeding. It has been demon-
55 strated that a short (12–72 h) period of complete ER (i.e. fasting)
56 causes several metabolic alterations, including a reciprocal
57 upregulation of lipolysis to provide NEFA for oxidation, and a
58 down-regulation of glycogenolysis to conserve glycogen
59 stores(12). This concurrently occurs with a decline in post-
60 prandial/nutrient-stimulated insulin sensitivity and elevated
61 plasma glucose concentrations(13). Typically, IER protocols uti-
62 lise partial (consuming approximately 25% EER) rather than
63 complete (i.e. fasting) ER, which may mitigate these effects(14).
64 It was recently shown in overweight/obese individuals that
65 partial ER (approximately 25% EER) produced a more favour-
66 able postprandial glycaemic response compared with complete
67 ER, but a degree of insulin resistance was still present(14).
68 However, metabolic regulation is likely to differ between lean
69 and overweight/obese individuals(15), as does the premise of
70 IER (i.e. weight loss v. weight maintenance). Weight manage-
71 ment is an integral part of reducing the prevalence of cardio-
72 metabolic disease. It has been well established that IER diets
73 induce weight loss, which may in itself impart a beneﬁcial effect
74 on risk markers for chronic disease. However, identifying
75 whether there are speciﬁc metabolic effects of IER style diets, in
76 lean individuals, will help determine whether IER might be used
77 effectively as a tool for weight management(16).
78 Therefore, the aim of this study was to investigate the acute
79 effects of 24-h severe ER (approximately 25% EER) in lean
80 males, on indices of glycaemic control and metabolism,
81 including fasting and postprandial measures of glucose, insulin,
82 NEFA, glucagon-like peptide 1 (GLP-1), glucose-dependent
83 insulinotropic peptide (GIP) and ﬁbroblast growth factor 21
84 (FGF21).
85 Methods
86 Subjects
87 This study was conducted according to the guidelines laid
88 down in the Declaration of Helsinki, and all procedures invol-
89 ving human subjects/patients were approved by the Lough-
90 borough University Ethical Sub-committee for human
91 participants (reference number: R15-P032). A total of fourteen
92 recreationally active, weight-stable (>6 months), non-dieting
93 males (age: 25 (SD 4) years; mass: 77·8 (SD 10·2) kg; height: 1·79
94 (SD 0·07)m; BMI: 24 (SD 2) kg/m2; body fat: 17 (4)%) provided
95 written informed consent to participate in the study. The sample
96 size was based on the 2-h glucose AUC values for males from a
97 previous study from our laboratory(11) that used a similar study
98 design. Using an α of 0·05 and a β of 0·2, it was determined that
99 twelve subjects would be required to detect a 10% difference in
100 glucose AUC.
101 Study design
102 Subject’s height (Seca stadiometer), mass (AFW-120K; Adam)
and body fat percentage(17) were determined during a
103preliminary visit to the laboratory. For inclusion, subjects were
104required to have a BMI <25 kg/m2 and/or a body fat percentage
105<25%(18). Subjects completed two experimental trials in a ran-
106domised, counterbalanced order, with trials separated by ≥7 d.
107Each trial consisted of a 24-h period of either EB or ER, followed
108by an oral glucose tolerance test (OGTT).
109Pre-trial standardisation
110Dietary intake and physical activity in the 24 h preceding the
111ﬁrst experimental trial were recorded, and replicated before the
112second trial. Alcohol and strenuous exercise were not permitted
113during this period, or during the study period.
114Protocol
115For each trial, subjects attended the laboratory on two con-
116secutive mornings (about 07.30 hours), arriving by means of
117motorised transport after a >10-h overnight fast. Subjects were
118not permitted to consume food and drink additional to that
119provided during the study period.
120Day 1: On arrival, subjects were seated for 30min before a
121blood sample was collected by venepuncture from an ante-
122cubital forearm vein (−24 h). Before leaving the laboratory,
123subjects were provided with an individually standardised
124diet, and instructions on when to consume each item. Sub-
125jects were asked to perform minimal activity over the day.
126Diets were formulated to contain either 25% (ER) or 100 %
127(EB) of EER, with EER calculated as the product of estimated
128resting metabolic rate(19) and a sedentary physical activity
129level of 1·4. Total energy was divided between four meals
130during EB and between two meals during ER (Table 1). Diets
131were kept standardised; however, individual preferences
132(i.e. severe dislike to a certain food) were considered and
133minor alterations were made to ensure adherence. Water
134intake was prescribed at 35ml/kg of body mass (2853 (SD
135329) ml) and was evenly distributed throughout the day. On
136ER, in place of breakfast (08.00 hours), subjects consumed a
137bolus of water equal to the water content of the breakfast
138provided on EB.
139Day 2: Subjects returned to the laboratory the following
140morning and a 20-gauge cannula was inserted into an ante-
141cubital forearm vein. After 30min of seated rest, a fasted blood
142sample was collected (0 h). Subjects then consumed 75 g of
143glucose dissolved in 250ml of water, with an additional 50ml of
144water used to rinse the beaker to ensure that all of the glucose
145was consumed. The drink was consumed as quickly as possible
146and typically within 15 s. Blood samples were collected 0·25,
1470·5, 0·75, 1, 1·5 and 2 h after ingestion, with subjects remaining
148seated throughout.
149Blood sampling and analysis
150Blood samples were drawn in 12-ml volumes, with 5ml dis-
151pensed into pre-chilled tubes containing 1·6mg/ml of potas-
152sium EDTA (Sarstedt AG & Co.) and stored on ice, and 5ml
153dispensed into tubes containing a clotting catalyst (Sarstedt
154AG & Co.) and stored for 15min at room temperature until
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155 completely clotted. Tubes were then centrifuged (1750 g;
156 10min; 4°C) and plasma/serum separated. The supernatant
157 was stored at −20°C for later analysis. The remaining 2ml of
158 whole blood was mixed with potassium EDTA and used for
159 the determination of Hb concentration (via the cyanmethae-
160 moglobin method) and haematocrit (via microcentrifugation)
161 to estimate changes in plasma volume, relative to −24 h(20).
162 Serum glucose (Horiba Medical) and plasma NEFA (Randox
163 Laboratories Ltd) concentrations were determined by enzy-
164 matic, colorimetric methods, using a bench-top analyser
165 (Pentra 400; Horiba ABX Diagnostics). The intra-assay CV for
166 serum glucose and plasma NEFA were 0·5 and 1·3%,
167 respectively. Plasma GLP-1 (Merck Millipore), GIP (Merck
168 Millipore), FGF21 (R&D Systems) and serum insulin (Immu-
169 nodiagnostic Systems) were analysed by enzyme-linked
170 immunosorbent assays. Intra-assay CV for plasma GLP-1,
171 GIP, FGF21 and serum insulin were 7·9, 6·1, 3·3 and 4·7%,
172 respectively. Serum glucose, insulin and plasma NEFA con-
173 centrations were determined at all sample time points. Plasma
174 GLP-1, GIP and FGF21 concentrations were determined at
175 −24, 0, 0·5, 1, 1·5 and 2 h.
176Calculations
177The updated homoeostatic model assessment of insulin resis-
178tance (HOMA2-IR) was used to calculate fasting insulin resis-
179tance before and after the dietary intervention using freely
180available online software (http://www.dtu.ox.ac.uk/homa-
181calculator/). Serum glucose and insulin concentrations from the
182OGTT were used to assess changes in whole-body insulin
183sensitivity using the Matsuda insulin sensitivity index(21).
184Incremental AUC (iAUC) was calculated for glucose and insulin
185to quantify the glycaemic response during the OGTT (0–2 h)(22).
186Total AUC (tAUC) was calculated for glucose and insulin, as
187well as all other variables, during the OGTT (0–2 h).
188Statistical analysis
189Data were analysed using IBM SPSS 23.0 (IBM). Correction of
190hormone concentrations relative to plasma volume change did
191not alter the results, and thus the unadjusted values are pre-
192sented. Fasted (−24–0 h) and postprandial changes (0–2 h) were
193analysed separately. All data were checked for normality using
194a Shapiro–Wilk test. Data containing one factor were analysed
Table 1. Energy and macronutrient intake at each meal (meal time in brackets) during day 1
(Mean values and standard deviations)
Energy balance Energy restriction
Mean SD Mean SD
Breakfast (08.00 hours)
Protein (g) 14 1 0 0
Carbohydrate (g) 89 7 0 0
Fat (g) 9 1 0 0
Fibre (g) 1 0 0 0
Energy (kJ) 2097 163 0 0
Foods Cereal, semi-skimmed milk and orange juice Water
Lunch (12.00 hours)
Protein (g) 46 3 36 3
Carbohydrate (g) 72 6 7 2
Fat (g) 29 3 3 1
Fibre (g) 5 0 2 0
Energy (kJ) 3124 243 874 68
Foods White bread, mayonnaise, chicken, lettuce, tomato, red pepper, balsamic vinegar
and chocolate-chip cookies
Chicken, lettuce, tomato, red pepper and
balsamic vinegar
Snack (16.00 hours)
Protein (g) 5 0 0 0
Carbohydrate (g) 31 2 0 0
Fat (g) 11 1 0 0
Fibre (g) 1 0 0 0
Energy (kJ) 1040 80 0 0
Foods Yogurt and cereal bar Not applicable
Dinner (19.30 hours)
Protein (g) 45 3 33 2
Carbohydrate (g) 138 11 55 4
Fat (g) 28 2 7 1
Fibre (g) 5 0 3 0
Energy (kJ) 4180 326 1748 136
Foods Pasta, Bolognese sauce, chicken, olive oil and chocolate-chip cookies Pasta, Bolognese sauce, chicken and
olive oil
Total
Protein (g) 110 7 69 4
Carbohydrate (g) 329 25 62 6
Fat (g) 78 8 10 1
Fibre (g) 12 1 4 0
Energy (kJ) 10 441 812 2622 204
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195 using a t-test or Wilcoxon signed-rank test, as appropriate. Data
196 containing two factors were analysed using a two-way repe-
197 ated-measures ANOVA, followed by post hoc Holm–Bonferroni-
198 adjusted paired t-tests or Holm–Bonferroni-adjusted Wilcoxon
199 signed-rank tests, as appropriate. Pearson’s r was used to
200 explore correlations between variables indicated in text. Data
201 sets were determined to be signiﬁcantly different when P< 0·05.
202 Data are presented as means and standard deviations unless
203 otherwise stated.
204 Results
205 Body mass change
206 Body mass was not different between trials at −24 h (P= 0·311)
207 but was lower at 0 h during ER (P< 0·05). Body mass decreased
208 between −24 and 0 h during both trials (P< 0·0001), but to a
209 greater extent during ER (EB: 0·43 (SD 0·31) kg; ER: 1·26 (SD
210 0·43) kg; P< 0·0001).
211 Fasting metabolic measures
212 Values for fasting variables collected before (−24 h) and after
213 (0 h) the dietary intervention are presented in Table 2. There
214 were trial (P< 0·05) and interaction (P< 0·001) effects, but no
215 time effect (P= 0·099), for serum glucose concentrations. Glu-
216 cose concentrations were lower at 0 h during ER compared with
217 EB (P< 0·01). Between −24 and 0 h, serum glucose concentra-
218 tions decreased during ER (P< 0·0001), but did not change
219 during EB (P= 0·578). There were time (P< 0·01) and inter-
220 action (P< 0·05) effects, but no trial effect (P= 0·079), for serum
221 insulin concentrations. Insulin concentrations were lower at 0 h
222 during ER compared with EB (P< 0·05). Between −24 and 0 h,
223 serum insulin concentrations decreased during ER (P< 0·01),
224 but did not change during EB (P= 0·178). There were time
225 (P< 0·01), trial (P< 0·05) and interaction (P< 0·05) effects for
226 HOMA2-IR, which was lower at 0 h during ER compared with
227 EB (P< 0·05) and decreased between −24 and 0 h during ER
228 (P< 0·01), but did not change during EB (P= 0·303; Fig. 1).
229There were time (P< 0·0001), trial (P< 0·05) and interaction
230(P< 0·0001) effects for plasma NEFA concentrations. NEFA
231concentrations were greater at 0 h during ER compared with EB
232(P< 0·0001). Between −24 and 0 h, plasma NEFA concentra-
233tions increased during ER (P< 0·0001), but did not change
234during EB (P= 0·166). There were no time (P= 0·545), trial
235(P= 0·227) or interaction (P= 0·628) effects for plasma GLP-1
236concentrations. There was a time effect (P< 0·01), but no trial
237(P= 0·088) or interaction (P= 0·096) effects, for plasma GIP
238concentrations. GIP concentrations decreased between −24 and
2390 h during ER (P< 0·05) and tended to decrease during EB
240(P= 0·055). There was a time effect (P< 0·0001), but no trial
241(P= 0·776) or interaction (P= 0·098) effects, for FGF21 con-
242centrations. Plasma FGF21 concentrations decreased between
243−24 and 0 h during ER (P< 0·0001) and EB (P< 0·01).
244Postprandial metabolic responses
245Glucose, insulin and NEFA. There were time (P< 0·0001), trial
246(P< 0·01) and interaction (P< 0·0001) effects for serum glucose
247concentrations, with lower concentrations at 0 h and greater
248concentrations between 0·75 and 1 h (P< 0·05; Fig. 2a) during
249ER compared with EB. Serum glucose iAUC (EB: 96
250(SD 74)mmol/l per 2 h; ER: 171 (SD 102)mmol/l per 2 h;
251P< 0·001; Fig. 2b) and tAUC (EB: 692 (SD 101)mmol/l per 2 h;
252ER: 757 (SD 107)mmol/l per 2 h; P< 0·001; Fig. 2b) were greater
253during ER than during EB, and there was a trend for
254greater peak glucose concentrations during ER (EB: 7·93
255(SD 1·52)mmol/l; ER: 8·44 (SD 1·46)mmol/l; P= 0·073). Glucose
256time-to-peak was delayed during ER compared with EB.
257There was no trial effect (P= 0·920), but there were time
258(P< 0·0001) and interaction (P< 0·001) effects for serum insulin
259concentrations, with greater insulin concentrations at 2 h during
260ER compared with EB (P< 0·05; Fig. 2c). Serum insulin iAUC
261was greater during ER than EB (EB: 23 335 (SD 10 964) pmol/l
262per 2 h; ER: 26 094 (SD 10 807) pmol/l per 2 h; P< 0·05; Fig. 2d),
263but tAUC was not different between trials (EB: 31 678
264(SD 11 598) pmol/l per 2 h; ER: 32 685 (SD 11 987) pmol/l per 2 h;
265P= 0·487; Fig. 2d). There were no differences between trials for
Table 2. Blood variables after 24-h energy-balance (EB) (100% estimated energy requirements (EER); EB) or severely energy-restricted diet (25% EER;
energy restriction (ER))
(Mean values and standard deviations)
EB ER
−24 h 0h −24 h 0 h
Mean SD Mean SD Mean SD Mean SD Interaction effect
Glucose (mmol/l) 5·4 0·4 5·5 0·6 5·3 0·3 5·0*† 0·4 0·002
Insulin (pmol/l) 76 32 70 30 76 34 55*† 20 0·029
HOMA2-IR 2·68 1·23 2·49 1·36 2·63 1·26 1·79*† 0·77 0·022
NEFA (mmol/l) 0·37 0·12 0·43 0·19 0·32 0·16 0·69*† 0·22 0·001
GLP-1 (pmol/l) 27 14 27 11 30 20 32 14 0·628
GIP (pmol/l) 59 26 50 31 77 47 48* 22 0·096
FGF21 (pg/ml) 102 63 71* 39 118 85 65* 47 0·098
HOMA2-IR, homoeostatic model assessment of insulin resistance; GLP-1, glucagon-like peptide-1; GIP, glucose-dependent insulinotropic peptide; FGF21, fibroblast growth
factor 21
* Values are significantly different from −24h during the corresponding trial (P<0·05).
† Values were significantly different from EB (P<0·05).
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Fig. 1. Bar chart (a) represents mean homoeostatic model assessment of insulin resistance (HOMA2-IR) values calculated from overnight fasting serum glucose and
insulin concentrations before (−24 h) and after (0 h) consumption of a 24-h energy-balanced (EB; ) or energy-restricted (ER; ) diet. Values are means, with standard
deviations represented by vertical bars. Line graph (b) shows individual HOMA2-IR values at 0 h during EB ( ) and ER ( ). * Values were significantly different from
EB at 0 h (P< 0·05). † Values were significantly different from −24h during ER (P< 0·05).
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Fig. 2. Serum glucose (a) and insulin (c) concentrations during a 2-h oral glucose tolerance test (OGTT) conducted after consumption of a 24-h energy-balanced (EB;
) or energy-restricted (ER; ) diet. Bar charts represent serum glucose (b) and insulin (d) incremental AUC (iAUC) and total AUC (tAUC) during the OGTT (0–2 h) for
EB ( ) and ER ( ). Values are means, with standard deviations represented by vertical bars. * iAUC values were significantly different from EB (P< 0·05). † tAUC
values were significantly different from EB (P< 0·05).
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Fig. 3. Plasma NEFA (a) concentrations during a 2-h oral glucose tolerance test (OGTT) conducted after consumption of a 24-h energy-balanced (EB; ) or energy-
restricted (ER; ) diet. Bar chart represents plasma NEFA (b) total AUC during the OGTT (0–2 h) for EB ( ) and ER ( ). Values are means, with standard deviations
represented by vertical bars. * Values were significantly different from EB (P< 0·05).
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266 peak serum insulin concentrations (EB: 452 (SD 168) pmol/l; ER:
267 433 (SD 163) pmol/l; P= 0·564) but time-to-peak was delayed
268 during ER compared with EB.
269 There were time (P< 0·0001), trial (P< 0·01) and interaction
270 (P< 0·0001) effects for plasma NEFA concentrations, with
271 greater plasma NEFA concentrations between 0 and 0·5 h dur-
272 ing ER compared with EB (P< 0·01; Fig. 3a). Plasma NEFA tAUC
273 was 45% greater during ER compared with EB (EB: 22·06 (SD
274 9·00)mmol/l per 2 h; ER: 32·09 (SD 9·44)mmol/l per 2 h;
275 P< 0·01; Fig. 3b).
276 Serum glucose iAUC and pre-OGTT (0 h) plasma NEFA
277 concentrations tended to be positively correlated (r 0·472;
278 P= 0·089), but serum glucose iAUC did not correlate with NEFA
279 tAUC (r −0·049; P= 0·868). Serum glucose tAUC did not corre-
280 late with either plasma NEFA tAUC (r 0·112; P= 0·703) or pre-
281 OGTT plasma NEFA concentrations (r 0·326; P= 0·255).
282 Matsuda index. The Matsuda index of insulin sensitivity
283 was not different between trials (EB: 7·50 (SD 4·75); ER: 7·93
284 (SD 5·06), P= 0·603).
285 Glucagon-like peptide 1 and glucose-dependent insulin-
286 otropic peptide. There was a time effect (P< 0·05), but no trial
287 (P= 0·219) or interaction (P= 0·055) effects, for plasma GLP-1
288 concentrations. GLP-1 tAUC was not different between trials
289 (EB: 3207 (SD 1321) pmol/l per 2 h; ER: 4123 (SD 3203) pmol/l
290 per 2 h; P= 0·155; Fig. 4b).
291 There was a time effect (P< 0·0001), but no trial (P= 0·473)
292 or interaction (P= 0·150) effects, for plasma GIP concentrations.
293 GIP tAUC was not different between trials (EB: 23 874
294(SD 10 283) pmol/l per 2 h; ER: 24 287 (SD 10 143) pmol/l per 2 h;
295P= 0·698; Fig. 4d).
296Fibroblast growth factor 21. There was a time effect
297(P< 0·01), but no trial (P= 0·513) or interaction (P= 0·763)
298effects, for plasma FGF21 concentrations. FGF21 tAUC was not
299different between trials (EB: 8000 (SD 4038) pg/ml per 2 h; ER:
3007553 (SD 5171) pg/ml per 2 h; P= 0·511; Fig. 5).
301Discussion
302The aim of this study was to determine the acute effects of 24-h
303severe ER on indices of insulin sensitivity. The results demon-
304strate that postprandial glycaemic control is impaired, despite a
305reduction in HOMA2-IR after 24-h severe ER. These ﬁndings
306may have implications for the efﬁcacy of IER diets, particularly
307for weight maintenance, where weight-loss-related improve-
308ments in insulin sensitivity might not be anticipated.
309Undergoing short periods of severe ER (consuming
310approximately 25% of EER) is a requisite component of an IER
311diet, and has been shown to be an effective method of reducing
312daily energy intake in lean(9,11) and overweight/obese(10,14)
313populations. In all, 3–12 weeks of IER has been demonstrated to
314cause signiﬁcant weight and fat mass losses, comparable to that
315achieved with moderate daily ER of similar duration(8). Impor-
316tantly, several studies have reported improvements in fasting
317insulin sensitivity indexes after 4–6 months of IER(6,23). In the
318current study, HOMA2-IR decreased 23% after 24 h of severe ER
319compared with an adequate energy intake control trial (EB).
320However, in response to an oral glucose challenge, serum
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AUC during the OGTT (0–2h) for EB ( ) and ER ( ). Values are means, with standard deviations represented by vertical bars.
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321 glucose tAUC was approximately 9% greater (iAUC was
322 approximately 78% greater) and serum insulin iAUC was
323 approximately 12% greater during ER compared with EB. In
324 addition, peak serum glucose concentration was 6% greater
325 and serum glucose remained elevated for longer, during ER.
326 These data suggest that glycaemic control was impaired after a
327 single 24-h period of severe ER in a group of young, lean men.
328 These results could be explained by a simple alteration in
329 substrate availability. A short period of severe ER may deplete
330 hepatic glycogen stores and reduce endogenous glucose pro-
331 duction(24). Consequently, circulating glucose and insulin are
332 also reduced(25). As HOMA2-IR is a product of fasting glucose
333 and insulin concentrations, these acute metabolic changes that
334 occur with severe ER limit the validity of HOMA2-IR to assess
335 insulin sensitivity in this context. The reduction observed in this
336 and similar studies may reﬂect a reduced requirement for
337 insulin secretion, rather than an improvement in insulin sensi-
338 tivity per se. Similarly, despite increases in fed-state serum glu-
339 cose and insulin concentrations during the OGTT, the
340 composite Matsuda index of insulin sensitivity was unaffected
341 by ER. This may be owing to the incorporation of fasting glu-
342 cose and insulin concentrations in the calculation of the
343 index(26,27).
344 When exogenous glucose availability is low, insulin con-
345 centrations are also low, stimulating lipolysis to mobilise TAG
346 for oxidation(28). As evidenced in the current study, this leads to
347 an increase in plasma NEFA concentrations, and previous stu-
348 dies, utilising a very similar ER protocol, have also reported an
349 increase in fat oxidation and a concomitant decrease in carbo-
350 hydrate oxidation in both the fasted and postprandial
351 state(10,11,14). A consequence of increased fat oxidation is the
352 accumulation of acetyl-CoA, NADH and citrate, which can
353 inhibit both upstream (via inhibition of phosphofructo-kinase)
354 and downstream (via inhibition of GLUT4 translocation and
355 pyruvate dehydrogenase (PDH)) glycolysis(29). Elevated plasma
356 NEFA concentrations have also been postulated to cause
357 mitochondrial overload, resulting in incomplete fatty acid oxi-
358 dation and the accumulation of toxic fatty acid intermediates,
359 such as diacylglycerol and ceramide, which may impair insulin
360 signalling(30). However, impairments in skeletal muscle insulin
361 signalling are not a prerequisite for reduced muscle glucose
uptake, and rapid impairments in the ability to process
362exogenous (ingested or infused) glucose might be explained by
363reduced glycolytic ﬂux/oxidative disposal. For example,
364Lundsgaard et al.(31) reported that 3 d of overfeeding with car-
365bohydrate increased leg glucose uptake during a hyper-
366insulinaemic–euglycaemic clamp, whereas 3 d of high-fat
367overfeeding reduced glucose uptake despite normal insulin
368signalling. It was suggested that greater TCA inﬂux from
369β-oxidation-derived acetyl-CoA might explain the reduced
370glucose uptake in the absence of changes in insulin signalling.
371Evidence for this was provided by the observations that high-fat
372diet adherence led to a signiﬁcant decrease in total PDH-E1α
373protein content (the enzyme responsible for catalysing the
374conversion of pyruvate to acetyl-CoA), as well as increased
375Ser300 phosphorylation (i.e. reduced PDH activity) and
376increased glucose-6-phosphate accumulation(31). Hence, in the
377context of the current study, elevated NEFA (a surrogate for
378increased lipolysis and greater dependency upon fat oxidation)
379likely decreased glucose uptake/oxidation by a similar
380mechanism.
381Several ﬁndings from the current study are analogous to a
382similar study that investigated the effects of 24-h severe ER in
383overweight and obese subjects(14). Postprandial insulin iAUC
384was greater after severe ER in the current study, a ﬁnding that
385differs from Antoni et al.(14), but average time to peak insulin
386concentration appeared to be delayed after severe ER in both
387studies, suggesting an impaired early-phase insulin response.
388Early-phase insulin has been shown to more potently
389lower blood glucose concentrations compared with late-phase
390insulin(32). This might therefore explain the greater peak
391glucose concentrations observed after severe ER in the current
392study and in the study by Antoni et al.(14). Together, these
393ﬁndings demonstrate that 24-h severe ER impairs glycaemic
394control in both lean (current study) and overweight/obese(14)
395subjects, with both studies indicating that early-phase insulin
396response may be a casual factor.
397This response is similar to the ‘second meal effect’, which
398describes an improved glycaemic response to a meal after
399consumption of glucose at a prior eating occasion(33). It is
400thought that the impairment in early-phase insulin response
401observed with the ‘second meal effect’ is mediated by pro-
402longed exposure of the pancreatic islet cells to elevated NEFA
403concentrations, shown in vitro to inhibit insulin secretion(34).
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404 Although this cannot be determined in the present study,
405 plasma NEFA concentrations were greater before the OGTT
406 during ER, indicating that plasma NEFA concentrations were
407 also probably greater during ER in the previous 24 h. This
408 would suggest that pancreatic islet cells were exposed to pro-
409 longed elevated plasma NEFA concentrations during ER, pos-
410 sibly leading to impaired early-phase response to the glucose
411 load. This is partially supported by a tendency for a positive
412 correlation between pre-OGTT plasma NEFA concentrations
413 and serum glucose iAUC, and an apparent delay in time-to-peak
414 insulin concentration during ER.
415 It is interesting to note that, despite several studies demon-
416 strating an impairment in glycaemic control after severe ER at
417 rest, a recent study found that restricting carbohydrate intake
418 after evening exercise improved postprandial glycaemic control
419 the following morning, compared with when carbohydrate was
420 consumed in a quantity equal to that expended during exercise
421 (90min running at 70% VO2max)
(35). This is quite different from
422 the present and previous studies, which have restricted total
423 energy intake during periods of minimal physical activity.
424 Under such conditions, ER will have little inﬂuence on muscle
425 glycogen content (the primary site of insulin-mediated glucose
426 disposal). It also demonstrates that the so-called (acute) insulin-
427 sensitising effect of exercise centres on creating a ‘sink’ for
428 glucose disposal. Further investigation is certainly necessary in
429 this ﬁeld as both exercise and dietary restriction are important
430 components of successful weight management strategies(36).
431 There are several biological mechanisms involved in the
432 regulation of energy homoeostasis. GLP-1 and GIP are incretin
433 hormones secreted rapidly from the intestine in response to
434 food ingestion(37). These hormones respond before nutrient
435 absorption, and stimulate the secretion of insulin from the
436 pancreas to assist with the disposal of glucose from the
437 blood(37). In the current study, although GIP was elevated after
438 consumption of the glucose solution in both trials, severe ER did
439 not appear to differentially affect circulating incretin hormone
440 concentrations, compared with an EB control trial. Plasma
441 GLP-1 and GIP concentrations were similarly unaffected by
442 short-term (7 d) high-fat (65% of energy) overfeeding
443 (approximately 150% EER), despite subjects in this study also
444 exhibiting impaired postprandial glycaemic control(38). It should
445 be noted that total GLP-1 and GIP were assessed in the current
446 study and in the study by Parry et al.(38), as opposed to the
447 biologically active (GLP-17–36; GIP1–42) form. However, asses-
448 sing total GLP-1/GIP is considered appropriate for estimating
449 the secretion of active GLP-1/GIP from the intestine(39). None-
450 theless, these studies suggest that incretin hormones are resis-
451 tant to short-term ﬂuctuation in EB and are unlikely to be
452 involved in acute impairments in glycaemic regulation in these
453 settings.
454 FGF21 is a novel hepatokine secreted in response to fasting
455 and feeding cycles(40), which positively correlates with obesity,
456 type 2 diabetes, insulin resistance and impaired glucose toler-
457 ance in humans(41,42). FGF21 is thought to be involved in
458 coordinating the adaptive response to ER via several mechan-
459 isms, such as encouraging ketosis, lowering blood glucose,
460 increasing insulin sensitivity and potentially modulating appe-
461 tite regulation via the agouti-related peptide and neuropeptide
462Y pathways(43). It should be noted that most studies that have
463found a physiological effect of ER on FGF21 have been rodent
464studies, with FGF21 concentrations shown to increase rapidly
465(within 6 h) after the onset of fasting(44). In contrast, human
466studies have observed no change in fasting or postprandial
467(OGTT) plasma FGF21 concentration after 16 h of fasting(45),
468and one study found that it may take 7–10 d of fasting to elicit
469an increase in FGF21 in humans(46). In line with this, the current
470study found no effect of 24-h severe ER on fasting or post-
471prandial plasma FGF21 concentrations. This strengthens evi-
472dence that nutritional regulation of FGF21 differs between
473rodents and humans(45).
474Although the exact mechanism of metabolic dysregulation
475may be elusive at present, results from several acute studies
476now indicate that a short period of severe ER leads to a sub-
477sequent period of impaired glycaemic control(9,11,14). The clin-
478ical signiﬁcance of these ﬁndings cannot be extrapolated from
479these acute studies, but oscillating postprandial glucose con-
480centrations are thought to directly contribute to the develop-
481ment of CVD(47), and a delay in the postprandial glucose curve
482is associated with impairments in β-cell function and insulin
483secretion(48). Whether these acute impairments in glycaemic
484control are improved or exacerbated with multiple restriction
485and refeeding cycles is not fully known. The only available
486data on long-term IER are from a rodent study, which found
487that 32 weeks of intermittent fasting and refeeding promoted
488redox imbalance, oxidative modiﬁcation of insulin receptors
489and a progressive decline in glucose tolerance, despite an initial
490improvement in glucose tolerance after 4 weeks(49). These
491data suggest that irregular feeding patterns leading to
492increased exposure to elevated blood glucose concentrations
493may have the potential to impair insulin-mediated glucose
494uptake.
495Future studies should investigate the long-term effects of an
496IER diet on glycaemic control in humans, including the dynamic
497assessment of glucose uptake and oxidation, as alterations may
498not be evident in the fasted state(16). A recent study(50) com-
499pared the effects of achieving approximately 5% weight loss via
500IER (consuming approximately 25% EER on two consecutive
501days, with a self-selected adequate-energy diet on the remain-
502ing 5 d of the week) or continuous ER (consuming 2510 kJ
503below EER for 7 d of the week), in a group of overweight/obese
504subjects. Fasted variables showed no difference between the
505dieting methods; however, postprandial insulin sensitivity
506markers revealed a signiﬁcant reduction in C-peptide after IER,
507whereas C-peptide was unaltered after continuous ER(50).
508C-peptide is secreted in equimolar amounts to insulin, but
509undergoes minimal extraction at the liver and thus may be a
510more robust measure of insulin secretion than circulating insulin
511concentrations(51). This change in C-peptide did not appear to
512inﬂuence postprandial glycaemic control, and comparable
513reductions in postprandial insulin concentrations were
514observed with both diets. However, this ﬁnding does indicate
515differences in mechanisms of action between IER and con-
516tinuous ER, potentially suggesting that IER may improve insulin
517sensitivity to a greater extent than continuous ER after semi-
518chronic (approximately 2 months) adherence. This warrants
519further investigation, as does identifying the effects of long-term
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520 IER in the absence of weight loss. This will be crucial for
521 determining whether IER can be used as an effective weight
522 maintenance strategy, with this being an important target for
523 reducing rates of obesity-related co-morbidities in the future(3).
524 In conclusion, this study has demonstrated that 24-h severe ER
525 leads to impaired postprandial glycaemic control, which cannot
526 be detected in the fasted state. These ﬁndings have implications
527 for IER diets and demonstrate the need for future studies to
528 identify the accumulative impact of repeated episodes of short-
529 term severe ER on glycaemic control in lean individuals.
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